• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report.

作者信息

Curtit Elsa, Thiery-Vuillemin Antoine, Nguyen Thierry, Heyd Bruno, Pivot Xavier, Di Martino Vincent, Borg Christophe

机构信息

Centre Hospitalier Universitaire de Besançon, Besançon, France.

出版信息

J Clin Oncol. 2011 Apr 20;29(12):e330-2. doi: 10.1200/JCO.2010.32.6785. Epub 2011 Jan 24.

DOI:10.1200/JCO.2010.32.6785
PMID:21263091
Abstract
摘要

相似文献

1
Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report.索拉非尼诱导晚期肝细胞癌完全组织学缓解：一例报告
J Clin Oncol. 2011 Apr 20;29(12):e330-2. doi: 10.1200/JCO.2010.32.6785. Epub 2011 Jan 24.
2
Sorafenib in advanced hepatocellular carcinoma.索拉非尼用于晚期肝细胞癌
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
3
Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.索拉非尼以外的晚期肝细胞癌的分子靶向治疗。
Expert Opin Pharmacother. 2010 Sep;11(13):2187-98. doi: 10.1517/14656561003724705.
4
[Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].索拉非尼（多吉美）用于肝细胞癌治疗：PRODIGE-AFEF建议
Gastroenterol Clin Biol. 2008 Jan;32(1 Pt. 1):3-7. doi: 10.1016/j.gcb.2007.11.001. Epub 2008 Mar 4.
5
Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.索拉非尼作为肝移植受者高危肝细胞癌辅助治疗的可行性和疗效
Exp Clin Transplant. 2010 Dec;8(4):307-13.
6
[Sorafenib in advanced hepatocellular carcinoma].
Internist (Berl). 2009 Nov;50(11):1290-2. doi: 10.1007/s00108-009-2489-5.
7
Clinical management and case reports for the treatment of hepatocellular carcinoma with sorafenib.索拉非尼治疗肝细胞癌的临床管理和病例报告。
J Clin Gastroenterol. 2011 Sep;45(8):733-7. doi: 10.1097/MCG.0b013e3181f68e83.
8
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.考虑到肝硬化的伴随阶段，索拉非尼在晚期肝细胞癌患者中的安全性和有效性。
J Clin Gastroenterol. 2009 May-Jun;43(5):489-95. doi: 10.1097/MCG.0b013e31818ddfc6.
9
Drug therapy: sorafenib.药物治疗：索拉非尼。
Hepatology. 2010 May;51(5):1843-9. doi: 10.1002/hep.23676.
10
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.索拉非尼治疗晚期肝细胞癌患者的II期研究。
J Clin Oncol. 2006 Sep 10;24(26):4293-300. doi: 10.1200/JCO.2005.01.3441. Epub 2006 Aug 14.

引用本文的文献

1
Liver resection and transplantation in the era of checkpoint inhibitors.免疫检查点抑制剂时代的肝切除与肝移植
JHEP Rep. 2024 Aug 6;6(11):101181. doi: 10.1016/j.jhepr.2024.101181. eCollection 2024 Nov.
2
Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies.酪氨酸激酶抑制剂靶向治疗的耐药机制及克服策略。
MedComm (2020). 2024 Aug 24;5(9):e694. doi: 10.1002/mco2.694. eCollection 2024 Sep.
3
The Current Status and Future Prospects for Conversion Therapy in the Treatment of Hepatocellular Carcinoma.
《转化治疗在肝细胞癌治疗中的现状与展望》
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231159718. doi: 10.1177/15330338231159718.
4
Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study.乐伐替尼联合抗程序性死亡蛋白1（PD-1）治疗是初始不可切除肝细胞癌患者可行的转化性切除策略：一项回顾性研究。
Front Oncol. 2022 Nov 24;12:1046584. doi: 10.3389/fonc.2022.1046584. eCollection 2022.
5
Resection of "down-staged" advanced hepatocellular carcinoma after treatment with the VEGFR2 inhibitor apatinib: five cases report.VEGFR2抑制剂阿帕替尼治疗后“降期”晚期肝细胞癌的切除术：五例报告
Transl Cancer Res. 2020 Aug;9(8):4999-5007. doi: 10.21037/tcr-19-3019.
6
Hepatocellular Carcinoma with Distant Metastasis Cured by 20-Day Sorafenib Treatment.经20天索拉非尼治疗治愈的伴有远处转移的肝细胞癌
Case Rep Gastroenterol. 2021 Jul 8;15(2):610-615. doi: 10.1159/000514529. eCollection 2021 May-Aug.
7
Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations.酪氨酸激酶抑制剂与抗PD-1抗体联合应用使初始不可切除的肝细胞癌降期并得以切除
Liver Cancer. 2021 Jul;10(4):320-329. doi: 10.1159/000514313. Epub 2021 Mar 30.
8
Complete Response for Advanced Hepatocellular Carcinoma by Conversion Surgery Therapy Following a Good Response of Regorafenib Despite Rapid Progressive Disease with Sorafenib.索拉非尼治疗后疾病快速进展，而regorafenib 治疗后疗效良好的情况下，行转化手术治疗晚期肝细胞癌的完全缓解。
Intern Med. 2021;60(13):2047-2053. doi: 10.2169/internalmedicine.5870-20. Epub 2021 Jul 1.
9
Pathological complete response by advanced hepatocellular carcinoma with massive macrovascular invasion to hepatic arterial infusion chemotherapy: a case report.巨块型大血管侵犯的晚期肝细胞癌经肝动脉灌注化疗达到病理完全缓解：1 例报告。
World J Surg Oncol. 2019 Dec 26;17(1):229. doi: 10.1186/s12957-019-1772-8.
10
Complete remission of advanced hepatocellular carcinoma following transient chemoembolization and portal vein ligation.经动脉化疗栓塞术联合门静脉结扎术后晚期肝细胞癌完全缓解
Surg Case Rep. 2018 Aug 29;4(1):102. doi: 10.1186/s40792-018-0510-8.